ArticleBritish journal of clinical pharmacology2015
Adverse drug reactions in neonates and infants: a population-tailored approach is needed.
Article in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 57 citations in OpenAlex.
- Global burden of adverse effects of medical treatment from 1990 to 2021: a Global Burden of Disease Study 2021.The Korean journal of internal medicine · 2026Article
- Safer breastfeeding with a wearable sensor for monitoring maternal acetaminophen transfer through breast milk.Device · 2025Article
- Assessment of severity and avoidability of adverse drug reactions in neonates: a reproducibility study of the Hartwig tool and LAAT.European journal of clinical pharmacology · 2025Observational
- Drug Safety During Breastfeeding: A Comparative Analysis of FDA Adverse Event Reports and LactMedPharmaceuticals (Basel, Switzerland) · 2024Article
- Treatment-related problems in neonates receiving parenteral nutrition: risk factors and implications for practice.BMC pediatrics · 2024Article
- Adverse drug reactions in neonates: a brief analysis of the FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- Observational
- Causality assessment of adverse drug reactions in neonates: a comparative study between Naranjo's algorithm and Du's tool.International journal of clinical pharmacy · 2023Observational
- Comparison of Dosing Accuracy Between the ENFit LDT and a Neonatal-Specific ISO-Compliant Enteral Syringe.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- An Artificial Intelligence Approach to Support Detection of Neonatal Adverse Drug Reactions Based on Severity and Probability Scores: A New Risk Score as Web-Tool.Children (Basel, Switzerland) · 2022Article
- Perioperative Care Structures and Non-Routine Events: Network Analysis.Studies in health technology and informatics · 2022Article
- Dose-Related Adverse Drug Events in Neonates: Recognition and Assessment.Journal of clinical pharmacology · 2021Review
- Exploratory Findings of Prescribing Unlicensed and Off-Label Medicines Among Children and Neonates.Integrated pharmacy research & practice · 2020Article
- Precision Dosing of Doxapram in Preterm Infants Using Continuous Pharmacodynamic Data and Model-Based Pharmacokinetics: An Illustrative Case Series.Frontiers in pharmacology · 2020Article
- Article
- Observational
- Drug related problems in the neonatal intensive care unit: incidence, characterization and clinical relevance.BMC pediatrics · 2019Observational
- Paediatric extrapolation: A necessary paradigm shift.British journal of clinical pharmacology · 2019Review
- Rational Use of Medicines in Neonates: Current Observations, Areas for Research and Perspectives.Healthcare (Basel, Switzerland) · 2018Review
- Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients.BMC pharmacology & toxicology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 4 countries.
Funding
Abstract
Drug therapy is a powerful tool to improve outcome, but there is an urgent need to improve pharmacotherapy in neonates through tailored prevention and management of adverse drug reactions (ADRs). At present, infants commonly receive off-label drugs, at dosages extrapolated from those in children or adults. Besides the lack of labelling, inappropriate formulations, (poly)pharmacy, immature organ function and multiple illnesses further raise the risk for ADRs in neonates and infants. Pharmacovigilance to improve the prevention and management of ADRs needs to be tailored to neonates and infants. We illustrate this using prevention strategies for drug prescription and administration errors (e.g. formulation, bedside manipulation, access), detection through laboratory signalling or clinical outlier data (e.g. reference laboratory values, overall high morbidity), assessment through algorithm scoring (e.g. Naranjo or population specific), as well as understanding of the developmental toxicology (e.g. covariates, developmental pharmacology) to avoid re-occurrence and for development of guidelines. Such tailored strategies need collaborative initiatives to combine the knowledge and expertise of different disciplines, but hold promise to become a very effective tool to improve pharmacotherapy and reduce ADRs in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.